Vinci Capital

Beqom SA is a company that specializes in employee compensation management and performance software solutions for large organizations across various industries worldwide. Founded in 2008 and based in Fribourg, Switzerland, Beqom provides a comprehensive platform that includes salary management, bonus management, long-term incentives, and sales performance management. The platform integrates with various systems, such as HRIS, ERP, finance, and payroll, enabling organizations to manage compensation effectively. Beqom's solutions are designed to enhance employee satisfaction and performance, making it easier for business managers to align and motivate their workforce. The company serves over 100 large clients globally, including notable names like Microsoft and Vodafone, focusing on optimizing performance, retention, and overall employee happiness.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, established in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for healthcare applications. Its flagship product, SENSIMED Triggerfish, is a single-use, soft hydrophilic contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The system includes various components such as disposable sensors, an adhesive antenna for data transmission, a battery-powered recorder, and software for data analysis. Sensimed aims to enhance clinical understanding of individual patient data by centralizing it in a registry, which allows for ongoing analysis to identify pathological patterns, personalize treatment, and evaluate treatment efficacy. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas.

Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.

SolvAxis is a leader in the design of ERP systems for SMEs . Since 1987, they offer enterprise software and related services. Their innovative and reliable ProConcept ERP solution lets you create and manage your business processes efficiently. 15'000 users on more than 1000 sites are already working with this standard solution. They are more and more numerous every day. Relationships with their customers, prospects and partners are based on mutual trust. Thus, their employees give your project a great importance. They collaborate with you in a close and constructive way.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies for patients with heart valve diseases, particularly aortic valve stenosis. The company focuses on enhancing patient care and safety by providing simple and accurate solutions for heart valve replacement. Its proprietary Acurate Aortic Valve Replacement System features a distinctive self-positioning design, which facilitates easy implant positioning and alignment, thereby improving the overall ease of use for healthcare providers. Through its advanced transcatheter aortic valve implantation devices, Symetis aims to address severe cardiac valve conditions and enhance treatment options within the healthcare industry.

Omnisens SA is a company that specializes in optic-based real-time asset integrity monitoring solutions tailored for the energy industry. Founded in 1999 as a spin-off from the Swiss Federal Institute of Technology, it provides a range of services including pipeline monitoring to detect leaks and prevent damage, cable condition monitoring, and structural health assessments. The company's technology leverages advanced fiber optic sensing methods, such as Distributed Temperature and Strain Sensing and Distributed Acoustic Sensing, to ensure continuous monitoring of critical assets. These solutions assist in early detection of potential threats to asset integrity, optimizing performance and enhancing safety. Omnisens serves vital sectors, including oil and gas, power, and civil engineering, delivering its products through system integrators and resellers across North America, Latin America, Europe, the Middle East, and Asia. With headquarters in Morges, Switzerland, and an additional office in Rio de Janeiro, Brazil, Omnisens has established itself as a leader in long-distance fiber optic sensing.

Sensimed AG is a medical devices company based in Lausanne, Switzerland, established in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for healthcare applications. Its flagship product, SENSIMED Triggerfish, is a single-use, soft hydrophilic contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The system includes various components such as disposable sensors, an adhesive antenna for data transmission, a battery-powered recorder, and software for data analysis. Sensimed aims to enhance clinical understanding of individual patient data by centralizing it in a registry, which allows for ongoing analysis to identify pathological patterns, personalize treatment, and evaluate treatment efficacy. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas.

Datamars was founded in 1988 as a joint venture between the technology companies Datalogic and Audemars to develop, design and manufacture state-of-the-art RFID solutions. The company quickly established itself as a world leader in RFID solutions for the animal and textile identification markets.

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the United Kingdom, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s orthobiologics pipeline products comprise MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion. The company has collaborations with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. Kuros Biosciences AG is based in Schlieren, Switzerland.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to the discovery and development of innovative small-molecule pharmaceutical products aimed at treating central nervous system (CNS) disorders. The company specializes in creating oral allosteric modulators that target G-protein coupled receptors, which are crucial for therapeutic interventions. Its leading programs include Dipraglurant, designed for treating levodopa-induced dyskinesia and dystonia in Parkinson’s disease, ADX71149 for epilepsy and other undisclosed CNS disorders, and a GABAB PAM aimed at addressing addiction. Addex Therapeutics has established a collaboration with Janssen Pharmaceuticals to advance the development of mGluR2PAM compounds for human health applications. Founded in 2002, the company has evolved its focus and pipeline based on a pioneering drug discovery platform that emphasizes allosteric modulation.